Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 778-781

  Lamba, Manisha ^a   Tafti, Bashir ^b   Melcher, Marc ^b   Chan, Gary ^a   Krishnaswami, Sriram ^a   Busque, Stephan ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

kidney transplantation; mycophenolic acid; pharmacokinetics; tasocitinib

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; BASILIXIMAB; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; PRIORITY JOURNAL; PROPHYLAXIS; STEADY STATE;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PYRIMIDINES; PYRROLES; TACROLIMUS;

EID: 78650284853     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f361c9     Document Type: Article

References (24)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
2. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
3. Hohage H, Zeh M, Heck M, et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc. 2005;37:1748-1750.
4. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
5. Gregoor PJ, de Sévaux RG, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
6. Smak Gregoor PJ, Van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999;14: 706-708.
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
8. Borie DC, Si MS, Morris RE, et al. JAK3 inhibition as a new concept for immune suppression. Curr Opin Investig Drugs. 2003;4:1297-1303.
9. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302: 875-878.
10. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science. 1994;266:1042-1045.
11. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005; 79:791-801.
12. Borie DC, Larson MJ, Flores MG, et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation. 2005;80: 1756-1764.
13. Busque S, Leventhal J, Brennan D, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9: 1936-1945.
14. Krishnaswami S. Pharmacokinetic profile of CP-690,550 in de novo renal allograft recipients. Transplantation. 2008;86(Suppl):414.
15. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation. 1992;53:428-432.
16. De Winter BC, Van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophe-nolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet. 2008;47:827-838.
17. Sam WJ, Akhlaghi F, Rosenbaum SE. Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. J Clin Pharmacol. 2009;49:185-195.
18. Le Guellec C, Bourgoin H, Büchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.
19. Van Hest RM, Van Gelder T, Vulto AG, et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083-1096.
20. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
21. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866-880.
22. Van Hest RM, Van Gelder T, Bouw R, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63:741-752.
23. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
24. Hesselink DA, Van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.